証拠の質 4.75/5
8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。
- D1 出典への根拠
- 5/5
- D2 出典の権威性
- 5/5
- D3 算術
- 4/5
- D4 不確実性
- 4/5
- D5 範囲
- 5/5
- D6 文章
- 5/5
- D7 認識の誠実性
- 5/5
- D8 注意事項の完全性
- 5/5
● あなたの要因 — このリスクをクリック ▾ して表示
- あなたの要因
認知リスク
前立腺がんは世間の心の中で奇妙な位置を占めている。ほとんどの男性は「8分の1」という診断の数字——女性の乳がんに付く見出しの数字とおおよそ同じ——を耳にしており、多くはそれを根拠に主要な脅威として整理する。典型的な読者が内面化していないのは、前立腺がんが一般的ながんの中で罹患率と死亡率の差が最も大きいという点だ：診断された男性の大多数はそれで死なず、高齢男性のかなりの割合が、症状をまったく引き起こさない組織学的に検出可能な前立腺がんを抱えている。スクリーニングの文献は10年以上にわたってこの差を公然と論じており、USPSTF はそれに応じて勧告を2度動かしてきた。世間の直感はその議論に追いついていない。
概算: 米国成人の50%ががんになることを非常にまたはある程度心配している（Gallup、全部位）。ほとんどの男性は8分の1という診断の数字を、はるかに低い死亡率と混同している。
出典: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
実際のリスク
世界全体で年間約397,000件の前立腺がん死亡（男性）
世界の男性、全年齢
計算を表示
WCRF / IARC GLOBOCAN 2022 は、世界全体で年間約1.47 million 件の前立腺がん新規症例と約397,430件の死亡を報告しており、これは全体で4番目に多いがん、男性では2番目に多いがんである。女性にリスクはなく（前立腺は男性のみの器官）、リスク集団は世界の成人男性、およそ3 billion 人である。年間約397,000件の死亡を約3 billion 人の成人男性にわたって割ると、平坦ハザードの基準で男性10,000人あたり年約1.3件となり、成人60年で素朴に累乗すると約0.8%になる。前立腺がんの死亡は70歳超に大きく集中している（SEER の前立腺がん死亡年齢の中央値は79歳）ため、これは上限ではなく下限であり、年齢加重は現実的な生涯の数字をより高く、今日生きている一般的な成人男性で1.5〜2.5%の範囲へと引き上げる。American Cancer Society の直接的な米国の数字は44分の1（約2.3%）であり、SEER の生涯診断の数字は約12.9%（おおよそ8分の1）で、97.9%の5年相対生存率によって長期の致死率は20%を十分に下回る。見出しの数字は世界の成人男性の基準値として0.02（約50分の1）であり、高い側は直接的な米国の数字、低い側は罹患率の低い地域（とくに東アジア）で挟み込まれる。女性は解剖学的にリスクがゼロであるため見出しから除外されている。スコープは、男性のみのリスク集団を本文と地域別内訳で明示したうえで、がん生涯の姉妹エントリに合わせるため global-adult-lifetime としている。2025年の傾向に関する注記（Kratzer et al., CA: A Cancer Journal for Clinicians）：米国の罹患率は約-6.4%/年（2007〜2014年）から2021年まで約+3.0%/年へと反転し、進行がんに集中している（領域+4.6%/年、遠隔+4.8%/年、2017〜2021年）一方、死亡率の低下は3.5%/年（1993〜2012年）から0.6%/年（2012〜2023年）へと鈍化した。これはステージシフト／発見遅れのシグナルであって、累積生涯死亡率の見出しの変化ではなく、それは不変である。
注意事項: 本エントリは前立腺がんによる生涯の死亡率であって、罹患率ではない。広く引用される「8分の1」という数字は、米国の男性が生涯に前立腺がんと診断される確率であり、そ…
本エントリは前立腺がんによる生涯の死亡率であって、罹患率ではない。広く引用される「8分の1」という数字は、米国の男性が生涯に前立腺がんと診断される確率であり、それで死亡する生涯確率は ACS によると約44分の1——およそ5.5倍小さい。診断と死亡の差は、本サイトの他のどの一般的ながんよりも前立腺がんで大きい。SEER によれば5年相対生存率は97.9%で他のどの一般的ながんよりも高く、高齢男性のかなりの割合が症状をまったく引き起こさない組織学的に検出可能な前立腺がんを抱えている：剖検研究では、無関係な原因で死亡した70歳超の男性の過半数に顕微鏡的な前立腺がんが見つかっている。これが、PSA スクリーニングに関する USPSTF の勧告が過去十五年で2度動き、いまなおその決定を定型ではなく個別のものと表現している主な理由だ——過剰診断と過剰治療が支配的な害であり、死亡率の便益は実在するものの小さく文脈に依存する。前立腺がんはまた解剖学的に男性のみの疾患であるため、見出しの数字の「世界の成人」という枠組みは、リスクを負うおよそ半分の成人にわたって人口加重されている。女性では確率はゼロであり、男性では生涯約50分の1という人口平均の数字が、緩慢な低悪性度の疾患（多くの男性が前立腺がんで死ぬのではなく前立腺がんを抱えたまま死ぬ）と侵攻性の高悪性度の疾患（5年生存率が急落する）との間の巨大な差を覆い隠している。黒人と白人の死亡率の差は米国のどの一般的ながんについても最大の人口統計学的格差であり、一部は生物学的、一部は構造的である——現在の証拠ではこの二つの寄与をきれいに分離できない。安心させる診断／死亡の差に反する近年の留意点が一つある：CA: A Cancer Journal for Clinicians の Kratzer et al. 2025 によれば、米国の前立腺がん罹患率は年約6.4%の低下（2007〜2014年）から2021年まで年約3.0%の増加へと反転しており、その上昇は進行がんに集中している——2017〜2021年に領域ステージの罹患率は年約4.6%、遠隔ステージは年約4.8%上昇した。同じ期間に前立腺がん死亡率の長期的な低下は、年約3.5%（1993〜2012年）から年約0.6%（2012〜2023年）へと急激に鈍化した。より後期での診断へのこのステージシフト——一部は2012年の USPSTF グレード D 勧告後の PSA スクリーニング減少に広く帰される——は、ここで用いる累積生涯死亡率の数字を変えないが、良好な生存統計が圧倒的に限局性の疾患に当てはまること、そして遠隔ステージの前立腺がんが全ステージの5年生存率の数字が示唆するよりもはるかに致死的であることを思い起こさせる。
リスクはどう変わるか
見出しの数値は大きく異なる状況の平均です。シナリオや文脈による確率の違いは以下の通りです:
50分の1 · 2.0%
~397K deaths/yr across ~3B adult men (WCRF / IARC GLOBOCAN 2022); age-weighted global adult lifetime figure
43分の1 · 2.3%
ACS direct SEER-based estimate: ~1 in 44 lifetime death alongside ~1 in 8 lifetime diagnosis
25分の1 · 4.0%
~2x higher mortality than white Americans per Siegel et al. 2024 in CA: A Cancer Journal for Clinicians; partly biology (higher incidence and more aggressive disease), partly differential access to timely screening and treatment
200分の1
Age-standardized prostate cancer mortality is an order of magnitude lower in East Asian populations than in men of European or African descent; the gap partly survives migration, suggesting a real genetic component alongside diet and screening differences
—
Not anatomically possible; women do not have a prostate gland
バーの長さと濃淡は、これらのシナリオを他のリスクとではなく、互いに比較して順位付けしたものです。正確な確率は各項目の横に表示されています。
関連するリスク
似たテーマの他のリスク — 関連する不安を探るために。
比較対象を選択
Prostate cancer kills about 397,000 men a year worldwide per the IARC’s GLOBOCAN 2022 totals (as republished by the World Cancer Research Fund), against roughly 1.47 million new cases — the 4th most common cancer globally and the 2nd most common in men. Age-weighted across a global adult-male population, that works out to a lifetime mortality figure near 1 in 50 for a generic man alive today. The American Cancer Society’s direct US figure is slightly higher, at 1 in 44 (about 2.3%). In the Likelier catalogue prostate cancer lands in roughly the same order of magnitude as colorectal, breast, and lung cancer deaths — mid-pack among cancers, well below cardiovascular disease, and several orders of magnitude above almost every non-disease entry on this site.
What makes prostate cancer unusual is the gap between those two numbers. The ACS also reports that about 1 in 8 US men will be diagnosed with prostate cancer in their lifetime, and SEER puts the 5-year relative survival at 97.9% — higher than for any other common cancer. A roughly 5.5x gap between diagnosis and death is the largest of any common cancer on this site, and it reflects something specific about the biology: a large share of prostate cancers are indolent, slow-growing, and clinically inconsequential. Autopsy studies have repeatedly found microscopic prostate cancer in a majority of men over 70 who died of unrelated causes. The blunt summary is that many men die with prostate cancer, not of it — and much of the “1 in 8” headline is disease that would never have killed anyone if it had not been found.
This is why PSA screening has been openly contested for the better part of two decades. The US Preventive Services Task Force gave prostate cancer screening a blanket Grade D (“recommend against”) in 2012, then upgraded to Grade C (“individual decision”) for men aged 55-69 in 2018 after longer follow-up from the European ERSPC trial showed a real but modest mortality benefit — roughly 1.3 prostate cancer deaths prevented per 1,000 men screened over 13 years. Against that, USPSTF estimates that 20-50% of screen-detected prostate cancers may be overdiagnosed, and treatment carries non-trivial rates of incontinence and erectile dysfunction. Screening remains Grade D for men 70+. The Likelier tag here is overrated in a narrow sense: the headline incidence number massively overstates the death risk, and the public reflex to treat “1 in 8” as a mortality figure is the main thing the numbers argue against. The disease itself is a major cancer that absolutely kills people; it just kills far fewer of the men it is found in than the diagnosis rate would suggest.
Where the headline does not apply: the demographic spread is wider than for most cancers on this site. Age dominates — SEER’s median age at prostate cancer death is 79, roughly 6 in 10 diagnoses occur at 65 or older, and the disease is rare before 40. Race matters more than for almost any other common cancer: Siegel and colleagues’ 2024 paper in CA: A Cancer Journal for Clinicians reports that prostate cancer mortality is roughly twice as high in Black men as in White men in the US, the largest racial gap for any common cancer. The disparity is partly biology (higher incidence and more aggressive disease at diagnosis in men of African descent) and partly structural (differential access to timely screening and treatment), and current evidence does not cleanly separate the two. East Asian men sit at the other end: age- standardized prostate cancer mortality is roughly an order of magnitude lower in East Asia than in North America or Sub-Saharan Africa, and the gap partially survives migration, suggesting a genuine genetic component alongside diet and screening differences. And because prostate cancer is male-only by anatomy, the global-adult framing of the headline number is a population-weighted average across the half of adults at risk. For women the probability is zero; for men, the honest one-line summary is a diagnosis figure near 1 in 8, a death figure near 1 in 44 in the US and 1 in 50 globally, and the reminder that those two numbers are not the same number.
関連する豆知識
前立腺がんは男性の約8人に1人に診断されるが、それで死ぬ確率は世界の成人男性で生涯1/約50に近い。多くは進行が遅く、別の原因が先に来ることが多い。
根拠台帳
以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。
5/6 件の出典が引用元と一字一句一致することを独立して検証済み
-
[1] World Cancer Research Fund International — Prostate cancer statistics 検証済み
Prostate cancer statistics- 統計値
1,467,854 new prostate cancer cases and ~397,430 deaths globally in 2022; 4th most common cancer worldwide and 2nd most common cancer in men- 抜粋
“"There were 1,467,854 new cases of prostate cancer in 2022. [...] Prostate cancer is the 4th most common cancer worldwide. It is the 2nd most common cancer in men." ”
- 出典データ
- 2024-05-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- WCRF republishes the IARC GLOBOCAN 2022 prostate cancer totals: ~1.47M new cases and ~397K deaths per year. Divided across ~3B adult men worldwide, that is ~1.3 per 10,000 per year on a flat-hazard basis. Age-weighting (prostate cancer mortality is concentrated above age 70, with a median age at death of 79 per SEER) pulls the realistic cumulative lifetime mortality near 1.5-2.5% globally. Used as the primary global headline and for the "4th most common / 2nd in men" framing in the body text. The ~3.7x ratio between global cases and deaths is the largest for any common cancer and is the central story of this entry.
- 独立性
- WCRF’s cancer statistics pages are a downstream republication of IARC GLOBOCAN 2022. Treated as partially dependent with any other IARC-derived source; used here because the direct IARC news release for GLOBOCAN 2022 does not break out prostate cancer totals in its text.
-
[2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Prostate Cancer 検証済み
Cancer Stat Facts: Prostate Cancer- 統計値
~12.9% US lifetime risk of prostate cancer diagnosis; 5-year relative survival 97.9% (2015-2021); median age at death 79; ~313,780 new cases and ~35,770 deaths estimated for 2025; age-adjusted death rate declining ~0.6% per year- 抜粋
“"Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID." ”
- 出典データ
- 2025-04-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- SEER gives direct US lifetime incidence of ~12.9% (the "roughly 1 in 8" that most men have heard). With 5-year relative survival of 97.9% and a median age at death of 79, the implied long-run case fatality is small: ~12.9% incidence multiplied by a roughly 15-20% long-run case fatality gives a US lifetime prostate-cancer-death probability near 2.0-2.5%, consistent with ACS’s direct "1 in 44" figure. Anchors the US row in the regional breakdown and the top of the Likelier uncertainty band. The 97.9% 5-year survival is the mechanism that creates the diagnosis/ death gap flagged in the body text — it is higher than the figure for any other common cancer.
- 独立性
- SEER (NCI) and IARC GLOBOCAN (WHO/WCRF) are methodologically independent compilation pipelines. SEER uses US vital registration and population- based cancer registries; IARC aggregates national registry data worldwide. The two are used here as independent anchors on the US and global ends of the regional breakdown.
-
[3] American Cancer Society — Key Statistics for Prostate Cancer 検証済み
Key Statistics for Prostate Cancer- 統計値
About 1 in 8 US men will be diagnosed with prostate cancer during their lifetime; about 1 in 44 will die of it; ~333,830 new cases and ~36,320 deaths projected for 2026- 抜粋
“"About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. [...] About 1 in 44 men will die of prostate cancer. [...] Prostate cancer risk is also higher in Black men in the US and the Caribbean. [...] About 6 in 10 prostate cancers are diagnosed in men who are 65 or older, and it is rare in men under 40." ”
- 出典データ
- 2026-01-16
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- ACS gives both the 1-in-8 diagnosis and the 1-in-44 death figure explicitly. The 5.5x gap between the two is the load-bearing fact for this entry and the main calibration story: readers reliably quote "1 in 8" as if it were a death rate, when it is in fact the incidence rate — the death rate is ~2.3%, an order of magnitude below what the headline implies. The age-skew ("6 in 10 diagnoses at 65 or older") and the race-disparity framing are used to support the body text and the regional_breakdown / personal_factor_multipliers blocks.
- 独立性
- ACS derives its US lifetime-probability figures from SEER incidence and mortality data. Treat these two as a single pipeline for US-specific numbers rather than as independent verification of each other.
-
[4] US Preventive Services Task Force — Final Recommendation Statement: Prostate Cancer: Screening 検証済み
Final Recommendation Statement: Prostate Cancer: Screening- 統計値
USPSTF recommends individual decision-making on PSA screening for men 55-69 (Grade C, upgraded from D in 2012); recommends against PSA screening for men 70+ (Grade D); notes 20-50% of screen-detected cases may be overdiagnosed- 抜粋
“"The decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one. [...] The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older." ”
- 出典データ
- 2018-05-08
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- USPSTF is the authoritative US primary-care screening guideline. The 2018 move from a blanket Grade D (recommend against) to Grade C (individual decision) for men 55-69 was a direct response to the longer-term ERSPC trial follow-up, which showed screening prevents about 1.3 prostate cancer deaths per 1,000 men screened over 13 years and reduces metastatic disease by about 3 per 1,000. That is a real but modest mortality benefit, set against a 20-50% overdiagnosis rate. Used here as the authoritative basis for the overdiagnosis framing in the body text and the myth_framing: overrated tag — "overrated" in the sense that the headline incidence figure massively overstates the death risk, not that the disease itself is not a major cancer.
- 独立性
- USPSTF evidence synthesis is methodologically independent of the SEER/IARC incidence-registry pipelines; it aggregates RCT and cohort evidence on screening effectiveness. Treated as an independent source here for the screening and overdiagnosis claims.
-
[5] Siegel RL, Giaquinto AN, Jemal A / CA: A Cancer Journal for Clinicians — Cancer statistics, 2024 検証済み
Cancer statistics, 2024- 統計値
Prostate cancer mortality rates are approximately two-fold higher in Black men than in White men in the US, alongside stomach and uterine corpus cancers- 抜粋
“"Compared to White people, mortality rates are two-fold higher for prostate, stomach and uterine corpus cancers in Black people." ”
- 出典データ
- 2024-01-17
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- Siegel et al. 2024 is the authoritative annual ACS peer-reviewed cancer statistics summary. The ~2x Black-vs-White prostate cancer mortality ratio is the canonical figure used for the African American row in the regional_breakdown block and the "African ancestry" row in personal_factor_multipliers. The gap reflects both biology (higher incidence and more aggressive disease at diagnosis in men of African descent) and differential access to timely treatment; the paper does not attempt to decompose the two contributions precisely. The overall prostate cancer death rate has been declining ~0.6% per year (per SEER), so the absolute gap is narrowing even as the ratio persists.
- 独立性
- Uses SEER incidence data and NCHS mortality data — same upstream as the SEER Stat Facts source above. Treated as a dependent but methodologically richer peer-reviewed analysis of the same pipeline.
-
[6] Kratzer TB, et al. / CA: A Cancer Journal for Clinicians — Prostate cancer statistics, 2025
Prostate cancer statistics, 2025- 統計値
US prostate cancer incidence reversed from −6.4% per year (2007-2014) to +3.0% per year through 2021, confined to advanced stage (regional +4.6%/yr, distant +4.8%/yr, 2017-2021); the mortality decline decelerated from 3.5% per year (1993-2012) to 0.6% per year (2012-2023); ~313,780 new cases and ~35,770 deaths estimated for 2025- 抜粋
“"Prostate cancer incidence trends have reversed from a decline of 6.4% per year during 2007 through 2014 to an increase of 3.0% annually during 2014 through 2021 [...] Over the past 5 data years (2017–2021), the rate has increased by 2.4% annually for localized-stage, 4.6% annually for regional-stage, and 4.8% annually for distant-stage disease [...] rapid declines of 3.5% per year from 1993 to 2012 have decelerated to 0.6% per year during 2012–2023." ”
- 出典データ
- 2025-09-01
- アクセス日
- 2026-06-14 · アーカイブ版
- 計算過程
- Kratzer et al. 2025 is the dedicated ACS peer-reviewed prostate cancer statistics report. It documents a recent reversal that the older diagnosis/death framing does not capture: after years of decline, US incidence began rising ~3.0% per year (2014-2021), and the rise is concentrated in advanced disease — regional-stage +4.6%/yr and distant-stage +4.8%/yr over 2017-2021. Meanwhile the long mortality decline has slowed sharply, from 3.5%/yr (1993-2012) to 0.6%/yr (2012-2023). This does NOT change the headline lifetime-mortality figure (still ~1 in 50 global / ~1 in 44 US per ACS/SEER) — that figure is a cumulative lifetime probability, not a year-over-year trend — but it supports the "stage-shift / late detection" caveat added to this entry and is consistent with the screening-pullback context already discussed via USPSTF. Used for the trend note in assumptions and the caveat.
- 独立性
- Uses SEER (NCI) incidence data and NCHS mortality data — the same upstream registry pipeline as the SEER Stat Facts and Siegel et al. sources. Treated as dependent on those for the underlying counts, but contributes the stage-specific and temporal-trend analysis those sources do not break out.